Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Kerendia patent expiration?

See the DrugPatentWatch profile for Kerendia

When does the Kerendia (finerenone) patent expire?

Kerendia (finerenone) is protected by multiple patents, so the answer depends on which specific patent and which country’s filing you mean. A patent-expiration date in one jurisdiction can differ from another, and some patents may end later than others.

What patents protect Kerendia, and why are there multiple “expiration” dates?

Brand medicines like Kerendia typically have several layers of IP protection, such as:
- compound or formulation patents on finerenone,
- process/manufacturing patents,
- additional patents tied to particular uses or dosing regimens,
- and sometimes data exclusivity or supplementary protection periods (which are not the same thing as “patent expiry”).

Because these protections end on different timelines, people often see multiple dates reported for the same product.

Do exclusivity periods end at the same time as patents for Kerendia?

No. Regulatory exclusivity (data exclusivity/market exclusivity, depending on the country) can prevent generic or biosimilar entry even after some patents expire, while other patents may keep additional competitors out even after exclusivity ends. So “patent expiration” and “earliest possible competitor launch” are often different.

Can generics or other competitors enter before all Kerendia patents expire?

Potentially, yes. Even with multiple patents, a generic manufacturer may be able to launch if it can rely on patent-expired claims (or avoid infringement by changing elements tied to remaining patents). The practical “earliest entry date” usually tracks which patents remain enforceable and how litigation plays out, not a single universal expiration date.

How can you find the exact Kerendia patent expiry date you care about?

To get an exact date, you generally need:
- the country (US, EU, UK, etc.),
- the specific patent number or family,
- whether you want “legal patent expiry” or “earliest time a generic/competitor can realistically launch.”

If you tell me the country (and, if you have it, the patent number or the source you’re looking at), I can narrow the answer to the relevant expiration timing for Kerendia in that jurisdiction.



Other Questions About Kerendia :

kerendia finerenone fda approval date bayer kerendia finerenone peak sales guidance 2026 chi ha brevettato kerendia ? Is kerendia expensive? Does kerendia lower blood sugar? Kerendia sales 2024? Kerendia 10 mg tablet?

AI-Drug Label Prescribing Information Alignment Report

90
90%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The only provided AI claim is supported by the FDA-approved Indications and Usage for Kerendia in adults with CKD associated with T2DM. No other dosing, safety, contraindication, or interaction claims were evaluated.


Category Scores

Indication
100
Excellent

Accurate Statements

Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with CKD associated with T2DM.
Section 1 (INDICATIONS AND USAGE): “Kerendia is indicated to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM).”

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
No safety-related claims, dosing instructions, contraindications, or monitoring statements were made beyond the on-label indication.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement
If additional label content is relevant (e.g., the heart failure indication or dosing/monitoring details), include and evaluate those sections as well.

Drug Brand Mention Assessment

Branding Score
26
Visibility
34
Mentioned
Ranking
#1
Sentiment
55
Recommendation Status
conditional
Brand Perception
Best Known For

Kerendia (finerenone) is protected by multiple patents


Core Claims
  • Answer depends on which specific patent and which country's filing you mean
  • Kerendia is protected by multiple patents
  • Patent-expiration date in one jurisdiction can differ from another
  • Some patents may end later than others
  • People often see multiple dates reported for the same product
Differentiators
  • Multiple patents have different end timelines
  • “Patent expiration” can differ from “earliest possible competitor launch”
  • Regulatory exclusivity can prevent entry even after some patents expire

Pricing Perception: Not Mentioned